Ardelyx (ARDX) shares fell nearly 22% in recent trading Friday after a federal judge dismissed the company's lawsuit against the Centers for Medicare and Medicaid Services.
The company was looking to block the health agency's plan to include Xphozah and other oral-only phosphate lowering therapies in its end-stage renal disease prospective payment system. It argued that the plan would make it difficult for patients to access the drugs.
However, Judge Beryl Howell of the US District Court for Washington, DC, decided against Ardelyx and allowed CMS to move forward with its rule which would take effect starting in 2025.
Ardelyx said it was reviewing the court's decision and will consider all options related to the lawsuit.
Ardelyx was joined by the American Association of Kidney Patients and the National Minority Quality Forum in the lawsuit.
Price: 4.99, Change: -1.40, Percent Change: -21.87
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。